Rocket Pharmaceuticals, Inc. (RCKT) income statement
RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$1.95−0.16 (-7.58%)
Close on Nov 20, 2026Market cap $214.06MP/E –Yield –
Rocket Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -60.3%
Financial strength
- Current ratio
- 9.24
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 716.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.58
- Dividend yield
- –
See a number that looks wrong?